Amgen reported $7.7 billion in net income for FY2025 — an 88.5% surge. But operating cash flow fell 13.3%, free cash flow collapsed 22%, and accounts receivable spiked 41% against just 10% revenue growth. Meanwhile, buried in the product revenue footnote: growth products overtook legacy at-risk drugs for the first time. The patent cliff narrative is partially obsolete — but a $12.3 billion debt maturity wall and negative ROIIC complicate everything.
Keysight Technologies reported record Q1 FY2026 revenue of $1.6 billion, beating consensus by $60 million with non-GAAP EPS of $2.17 topping estimates by 9%. But the 10-Q reveals a $101 million tax benefit from an audit settlement drove the effective tax rate to -42%, inflating GAAP EPS by approximately 40%. Beneath the tax windfall, 14% organic growth — double the FY2025 pace — and a 96% Q/Q cash flow surge to $441M with 1.57x cash conversion signal a genuine inflection in Keysight's demand trajectory, driven by AI data center infrastructure buildout.
Chevron's FY2025 10-K reports a 106% dividend payout ratio — the company paid more in dividends than it earned. But operating cash flow tells the opposite story, covering the dividend 2.6 times. The $73.5 billion Hess PP&E step-up created the widest cash-vs-earnings divergence among supermajors, collapsed ROIC from 9.5% to 5.9%, and transformed Chevron from the least leveraged to the most leveraged in its peer group. Here's what the filing reveals about dividend safety, balance sheet risk, and when the Hess bet might pay off.
AMD generates $1.72 in cash per $1 of profit—the best in semiconductors—while NVIDIA manages only $0.84. This signals AMD's earnings are higher quality and more sustainable despite NVIDIA's explosive growth.